Volume 30, Number 1—January 2024
Research Letter
Pseudomonas guariconensis Necrotizing Fasciitis, United Kingdom
Edward J. Moseley
, Jian Cheng Zhang, and O. Martin Williams
, Jian Cheng Zhang, and O. Martin Williams
Table
Antimicrobial susceptibility data for blood culture isolates in a case of Pseudomonas guariconensis necrotizing fasciitis, United Kingdom*
| Antimicrobial agent |
Admission blood culture by ViTek 2† (MIC, mg/L) |
8-h blood culture |
Tissue culture by disc diffusion‡ |
|
|---|---|---|---|---|
| Disc diffusion‡ |
Gradient strip (MIC, mg/L) |
|||
| Ceftazidime | I (4) | I | ND | I |
| Ciprofloxacin | I (<0.25) | I | ND | I |
| Gentamicin | S (<1) | S | ND | S |
| Meropenem | I (4) | I | I (4) | I |
| Tobramycin | S (<1) | S | ND | S |
| Piperacillin/tazobactam | R (64) | I | I (16) | I |
| Amikacin | S (<2) | ND | ND | ND |
| Cefepime | I (2) | ND | ND | ND |
| Imipenem | I (1) | ND | ND | ND |
| Levofloxacin | I (0.5) | ND | ND | ND |
| Ticarcillin/clavulanic acid | R (>128) | ND | ND | ND |
*All breakpoints are European Committee on Antimicrobial Susceptibility Testing (EUCAST) clinical breakpoints version 11.0, except gentamicin disk diffusion testing, for which EUCAST version 9.0 was used. I, susceptible, increased exposure; ND, not done; R, resistant; S, susceptible. †bioMérieux, https://www.biomerieux.com. ‡Using methods from EUCAST (1).
Page created: November 13, 2023
Page updated: December 20, 2023
Page reviewed: December 20, 2023
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.